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A B S T R A C T
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a polyglutamine
expansion mutation in the huntingtin protein. Expansions above 40 polyglutamine repeats are invariably fatal,
following a symptomatic period characterised by choreiform movements, behavioural abnormalities, and cog-
nitive decline. While mutant huntingtin (mHtt) is widely expressed from early life, most patients with HD
present in mid-adulthood, highlighting the role of ageing in disease pathogenesis. mHtt undergoes proteolytic
cleavage, misfolding, accumulation, and aggregation into inclusion bodies. The emerging model of HD patho-
genesis proposes that the chronic production of misfolded mHtt overwhelms the chaperone machinery, diverting
other misfolded clients to the proteasome and the autophagy pathways, ultimately leading to a global collapse of
the proteostasis network. Multiple converging hypotheses also implicate ageing and its impact in the dysfunction
of organelles as additional contributing factors to the collapse of proteostasis in HD. In particular, mitochondrial
function is required to sustain the activity of ATP-dependent chaperones and proteolytic machinery. Recent
studies elucidating mitochondria-endoplasmic reticulum interactions and uncovering a dedicated proteostasis
machinery in mitochondria, suggest that mitochondria play a more active role in the maintenance of cellular
proteostasis than previously thought. The enhancement of cytosolic proteostasis pathways shows promise for HD
treatment, protecting cells from the detrimental eﬀects of mHtt accumulation. In this review, we consider how
mHtt and its post translational modiﬁcations interfere with protein quality control pathways, and how the
pharmacological and genetic modulation of components of the proteostasis network impact disease phenotypes
in cellular and in vivo HD models.
1. Introduction
Huntington’s Disease (HD) is a neurodegenerative disease caused by
a CAG repeat expansion mutation in the exon 1 of the huntingtin (Htt)
gene. Mutant Htt (mHtt) thus contains an expanded polyglutamine
(polyQ) tract in the N-terminal region, which is considered a main
driver of mHtt proteotoxicity. HD has an estimated prevalence of 4–10
per 100,000 individuals in the Western world (Ross and Tabrizi, 2011),
with worldwide variation surpassing tenfold diﬀerences between dis-
tinct geographical regions (Rawlins et al., 2016). Expansions of 40 or
more polyQ are fully penetrant, and the greater the number of tandem
repeats, the earlier is the age of onset (Squitieri and Jankovic, 2012).
Despite the widespread mHtt expression, HD neurodegeneration is
particularly severe in the striatum, where a combination of intrinsic
vulnerability and non-cell autonomous factors preferentially kills GA-
BAergic medium spiny neurons while sparing striatal interneurons
(Ehrlich, 2012; Fu et al., 2018). Clinically, the disease is characterized
by a progressive extra-pyramidal motor dysfunction, psychiatric dis-
turbance and cognitive decline (Ross et al., 2014). Although mHtt is
expressed throughout the life of the individual, HD onset typically oc-
curs around the 4th decade of life. This suggests that there are com-
pensatory mechanisms that limit mHtt proteotoxicity early in life, but
that such mechanisms are eventually overtaken by ageing and disease
progression (Arrasate and Finkbeiner, 2012).
The cellular proteome is maintained by the coordinated activity of a
protein homeostasis (proteostasis) network, which regulates protein
synthesis, folding, transport and degradation (for a recent review, see
Labbadia and Morimoto, 2015). The proteostasis network can be in-
duced in response to protein misfolding and aggregation, and comprises
several quality control systems, such as molecular chaperones and
proteolytic pathways (Hipp et al., 2014). Molecular chaperones assist
protein folding and disaggregation (Hartl et al., 2011; Nillegoda et al.,
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2018). Chaperones of the heat shock protein (Hsp) 90 and Hsp70 fa-
milies are the main eﬀectors of the proteostasis network, acting to-
gether in a multiprotein complex that includes co-chaperones such as
Hsp40 (J-protein) (Pratt et al., 2015). When misfolded proteins escape
chaperone control they are usually targeted for degradation, either
through the ubiquitin-proteasome system (UPS) or by autophagy (Hipp
et al., 2014). The UPS is the main route of protein degradation in
mammalian cells, acting in both cytoplasm and nucleus, whereas au-
tophagy functions mainly in the cytoplasm (Hipp et al., 2014; Li and Li,
2011).
UPS-mediated degradation depends on the recognition of protein
substrates that have been ﬂagged through polyubiquitination
(McKinnon and Tabrizi, 2014), a process catalysed by a triple enzy-
matic cascade, involving an E1 ubiquitin activator, an E2 conjugase and
an E3 ligase (Dantuma and Bott, 2014). Polyubiquitinated proteins are
recognized by the 26S proteasome for degradation. The 26S proteasome
is an ATP-dependent proteolytic complex constituted by one or two 19S
regulatory particles, and a 20S core particle. The regulatory particle
recognizes, deubiquitinates and unfolds the substrate, which is then
translocated to the cavity of the core particle, where multiple catalytic
sites mediate its degradation (Li and Li, 2011; McKinnon and Tabrizi,
2014; VerPlank and Goldberg, 2017).
Autophagy-associated pathways for the clearance of cytosolic sub-
strates converge on lysosomal degradation, and are broadly categorised
as micro-, macro- and chaperone–mediated autophagy (CMA) (Cortes
and La Spada, 2014). In microautophagy, cytosolic components are
directly engulfed by the lysosome (Shpilka and Elazar, 2011). In CMA,
soluble proteins are directly translocated into the lysosome after re-
cognition of a KFERQ-like motif by the molecular chaperone Hsc70. In
macroautophagy (hereafter referred to as autophagy) cytosolic sub-
strates are engulfed by a double membrane structure, the autophago-
some, which subsequently fuses with lysosomes (Cortes and La Spada,
2014). A more recent concept is that of selective autophagy, meaning
the selective degradation of substrates recognized by speciﬁc autop-
hagic receptors, such as p62 (Menzies et al., 2015; Wong and Holzbaur,
2015).
Data from HD patients and experimental models indicate that the
accumulation and aggregation of mHtt are associated with a dysfunc-
tional proteostasis network (Margulis and Finkbeiner, 2014; Sieradzan
et al., 1999). A better understanding of the mechanisms by which mHtt
interferes with protein quality control and degradation pathways, and
how these pathways can be modulated, may oﬀer new therapeutic
avenues for HD. In the ﬁrst section of this paper, we review the evi-
dence for impaired proteostasis in HD. We consider the interplay be-
tween diﬀuse and aggregated mHtt, the stress imposed by such mHtt
species on molecular chaperones and proteolytic pathways, and how
this might synergise with ageing-associated changes in the proteostasis
network. We address recent ﬁndings concerning impairments in au-
tophagy and the potential contribution of a loss on normal Htt function.
Moreover, we consider the emerging concept of mitochondrial pro-
teostasis and how the dysfunction of this organelle in HD may impact
the cellular proteostasis network. In the second section, we review re-
cent data from HD models with genetic and pharmacological modula-
tion of speciﬁc targets in the proteostasis network. We conclude with a
discussion of the current model of impaired proteostasis in HD, how it
might relate to selective neurodegeneration, and the implications for
future directions of research in this ﬁeld.
Fig. 1. Collapse of proteostasis in HD. Chronic production of misfolded mHtt titrates chaperones, which acts synergistically with ageing through decreasing
chaperone availability and thus leading to the misfolding and accumulation of other chaperone client proteins. The latter are diverted to the proteasome, exceeding
its capacity, and causing UPS impairment (Hipp et al., 2014, 2012). Energy-dependent protein clearance pathways can be further impaired when ATP production is
limited by mitochondrial dysfunction. Proteostasis collapse increases the levels of diﬀuse mHtt, which may trigger apoptosis or promote aggregation into inclusions
bodies (IBs). By sequestering mHtt, IBs can extend survival, but they also recruit proteostasis components, in a vicious cycle that gradually disrupts cellular
homeostasis, promoting a quiescent state that eventually culminates in necrosis (Ramdzan et al., 2017).
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2. Section I - how is proteostasis impaired in HD?
2.1. The interplay of diﬀuse and aggregated mHtt
The aggregation of mHtt into inclusion bodies (IBs) is considered
one of the central hallmarks of HD, although their role in HD patho-
genesis remains incompletely understood (Margulis and Finkbeiner,
2014). The detection of IBs in cortical and striatal brain regions aﬀected
by HD (DiFiglia et al., 1997), as well as the observation of symptomatic
rescue in HD mice treated with aggregation inhibitors, have supported
the notion that IBs are toxic (Katsuno et al., 2004; Tanaka et al., 2004).
However, the opposite notion that IBs are a coping response has been
promoted by longitudinal survival analyses in cell models, which have
revealed that the levels of diﬀuse mHtt predict death or IB formation,
and that the latter decreases diﬀuse mHtt and increases survival
(Arrasate et al., 2004). IB formation thus seems to reduce the levels of
diﬀuse toxic species of mHtt (Arrasate et al., 2004), and also to rescue
UPS impairment in HD cellular models (Mitra et al., 2009). Subse-
quently, it was proposed that diﬀuse mHtt might inhibit the proteasome
indirectly, by saturating the protein folding machinery and diverting an
excess of other misfolded/ubiquitinated proteins to the UPS that then
becomes impaired (Bersuker et al., 2016; Hipp et al., 2012) (Fig. 1).
Several studies associate the toxicity of IBs with their ability to es-
tablish aberrant interactions with the proteome, and to sequester key
cellular components such as proteostasis machinery (Gasset-Rosa et al.,
2017; Park et al., 2013; Seidel et al., 2016). Hsp40 chaperones, which
mediate the delivery of misfolded proteins to the nucleus for protea-
somal degradation, were sequestered in IBs in yeast expressing mHtt
and in brains of HD patients (Park et al., 2013; Seidel et al., 2016). Also,
the constitutive Hsp70 (Hsc70), involved in protein folding, degrada-
tion, and prevention of aggregation, was sequestered in IBs in HD cell
models (Yu et al., 2014). The toxicity of IBs also involves the physical
disruption of cellular structures, as recently shown for the nuclear en-
velope (Gasset-Rosa et al., 2017) and ER membranes (Bauerlein et al.,
2017). IBs in the cytosol obstruct intracellular traﬃcking (Chang et al.,
2006), and were shown to impair the nucleocytoplasmic transport of
proteins and RNA by sequestering proteins involved in nuclear trans-
port (Woerner et al., 2016). Increases in nuclear IBs have also been
correlated with increased cytotoxicity, as found in a study that depleted
a key element of the ribosomal quality control (RQC) system (Zheng
et al., 2017). Another study showed that RQC impairment promotes the
occurrence of multiple small mHtt aggregates, instead of a single large
aggregate, and that the former are more toxic and disrupt the actin
cytoskeleton (Yang et al., 2016). Although further mechanistic studies
are necessary, these studies suggest that altered activity of the RQC
system may play an important role in mHtt aggregation and associated
toxicity.
Thus, a consensus is emerging to suggest that mHtt aggregation into
IBs plays a dual role, combining protective and toxic eﬀects. Cells ex-
pressing high levels of diﬀuse mHtt are more likely to initiate apoptosis.
Cells that form IBs show decreased levels of diﬀuse mHtt, but pro-
gressively convert into a quiescent state as the IBs also sequester other
crucial proteins. While this process may extend survival, it also gra-
dually disrupts cellular homeostasis and leads to cellular dysfunction
(Ramdzan et al., 2017) (Fig. 1).
2.2. Impairment of autophagy in HD and Htt loss of function
Disruptions in autophagy are thought to contribute to the patho-
genesis of HD (Martin et al., 2015). The eﬀects of mHtt along the au-
tophagic pathway are multiple and pleiotropic, as mHtt interferes with
processes such as autophagosomal dynamics and initiation of autop-
hagy (Martin et al., 2015). Mechanistically, mHtt may disturb or fail to
mimic the physiological roles of wild-type Htt in regulating autopha-
gosomal transport (Wong and Holzbaur, 2014), autophagosomal cargo
loading, or the activity and levels of key initiators of the autophagy
pathway, such as ULK1 and Beclin-1 (Rui et al., 2015a; Wold et al.,
2016; Ashkenazi et al., 2017), as detailed below.
Data from HD cell models where autophagosomes contained little
cytosolic cargo suggested that mHtt may impair cargo recognition
(Martinez-Vicente et al., 2010). Alternatively, studies in neurons sug-
gested that mHtt impairs the autophagosomal transport regulation ex-
erted by wild-type Htt and its associated protein HAP-1 (Wong and
Holzbaur, 2014). Consequently, mHtt disrupts the axonal transport of
autophagosomes, without altering their formation or cargo loading, but
reducing autophagosome-lysosome fusion events, thereby leading to
insuﬃcient lysosomal acidiﬁcation and impaired degradation of cargo
(Wong and Holzbaur, 2014).
Fibroblasts from HD patients showed reduced levels of a key in-
itiator of autophagy – beclin-1 (Ashkenazi et al., 2017). The authors
proposed that mHtt competes with the deubiquitinase ataxin-3 for be-
clin-1 binding, thus increasing the ubiquitination and proteasomal de-
gradation of beclin-1 and thereby impairing initiation of autophagy
(Ashkenazi et al., 2017). Dysfunction in the initiation of autophagy was
also attributed to the loss in mHtt of a physiological function of wild-
type Htt in selective autophagy (Rui et al., 2015a, b). Htt interacts with
the autophagy adaptor p62, aﬀecting its aﬃnity for substrates and for
LC3, and it also interacts with and modulates the activation of ULK1 – a
regulatory kinase involved in autophagy activation. Htt may thus act as
a scaﬀold that brings together the machinery required for cargo re-
cognition and initiation of autophagy (Rui et al., 2015a). Supporting
this hypothesis, an independent study showed a reduced activity of
ULK1 and Vsp34 kinases in HD cellular and animal models (Antonioli
et al., 2017; Wold et al., 2016).
The hypothesis that Htt acts as an autophagy-promoting scaﬀold is
further supported by the high similarity between Htt and the Atg11
protein that mediates selective autophagy in yeast (Ochaba et al.,
2014). Consistently, expression of full-length Htt lacking a polyQ
stretch (ΔQ-Htt) enhanced neuronal autophagy in HD mice (Hdh140Q/
ΔQ) (Zheng et al., 2010), suggesting that polyQ expansion in Htt dis-
rupts its physiological role as an autophagy-promoting scaﬀold. These
studies highlight the importance of selectively targeting mHtt, as
treatments that non-selectively decrease the levels of both mutant and
wild-type Htt might aggravate dysfunctional autophagy.
2.3. Mitochondrial dysfunction and impaired proteostasis in HD
Multiple abnormalities in mitochondrial bioenergetics, dynamics
and quality control have been associated with HD pathogenesis
(Damiano et al., 2010; Guedes-Dias et al., 2016; Oliveira, 2010). Such
abnormalities contribute to energy impairment in HD, whose nature is
more dynamic than previously thought, as shifts in metabolic ﬂux occur
as compensatory homeostatic mechanisms throughout the disease (for a
recent review see Dubinsky, 2017). Mechanistically, mHtt is proposed
to exert indirect eﬀects on mitochondria and energy metabolism via
transcriptional deregulation, and also direct eﬀects by physically in-
teracting with the organelle and associated proteins. While mitochon-
drial respiratory chain impairment in HD is currently considered a late,
secondary event, bioenergetic eﬃciency may be compromised by
changes in mitochondrial dynamics, as mitochondrial structural re-
modelling is linked with the adaptation to energetic demands (Liesa
and Shirihai, 2013), and also because neuronal processes require op-
timal mitochondrial distribution and size adaptation (Misgeld and
Schwarz, 2017).
Increased mitochondrial fragmentation has been observed in several
HD models and patients’ brains and linked to dysregulation of ﬁssion
and fusion proteins. mHtt directly interacts with the ﬁssion promoter
Drp1 or induces its post-translational modiﬁcation, enhancing its ac-
tivity (Cherubini and Gines, 2017). Moreover, mHtt disrupts mi-
tochondrial traﬃcking and mitophagy as aggregates may physically
obstruct intracellular organellar dynamics, while diﬀuse mHtt may also
interfere with traﬃcking adaptor/regulatory proteins, aﬀecting
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mitochondrial and autophagosomal dynamics (Guedes-Dias et al.,
2016).
The association of mHtt with mitochondria increases with age and
disease progression (Orr et al., 2008; Shirendeb et al., 2011; Yano et al.,
2014). mHtt was found to interact with Tim23, a component of the
import machinery at the inner mitochondrial membrane (IMM), and
this interaction was proposed to inhibit protein import (Yano et al.,
2014). Import deﬁciency may be an early event in HD pathology and
mediate downstream alterations in mitochondrial respiration and
morphology (Franco-Iborra et al., 2018). While further studies are still
necessary, the interaction of mHtt with IMM components raises the
possibility that mHtt itself may be imported into the mitochondria.
Interestingly, it was recently proposed that cytosolic aggregation-prone
proteins can be imported into the mitochondria and degraded by mi-
tochondrial proteases (Ruan et al., 2017). Additionally, when cytosolic
proteostasis is impaired there is an accumulation of misfolded proteins
in the mitochondria, which in turn induces mitochondrial stress (Ruan
et al., 2017). It is thus possible that mHtt, by disrupting cytosolic
proteostasis, overwhelms and impairs the mitochondrial proteolytic
machinery, inducing a stress response known as the mitochondrial
unfolded protein response (mtUPR). A mechanism that induces the
mtUPR is the decrease in the mitochondrial protease HtrA2 (Moisoi
et al., 2009). In fact, HtrA2 levels were found to be reduced in primary
neurons expressing mHtt (Inagaki et al., 2008; Tagawa et al., 2007).
Thus, it would be interesting to explore if the mtUPR is activated in HD
and how this stress response might modulate mHtt proteostasis and
neuronal survival.
A likely consequence of mHtt-induced mitochondrial dysfunction is
a decrease in ATP availability, which restricts ATP-dependent activities
of the proteostasis network (Hutt and Balch, 2013) and may also limit a
potential hydrotrope function of ATP on protein solubility (Patel et al.,
2017), thus impairing mHtt clearance and promoting its aggregation
(Fig. 1). In addition to the ATP limitation, mitochondrial dysfunction
may impair the autophagic component of proteostasis by other me-
chanisms. One possibility is that mitochondrial dysfunction disrupts ER-
mitochondrial contacts, compromising autophagosome formation
which seems to be enriched at those sites (Hailey et al., 2010; Hamasaki
et al., 2013). Moreover, mitochondrial dysfunction may disturb the
mitochondria–lysosome reciprocal regulation (Wong et al., 2018), and
impair the normal lysosomal function (Demers-Lamarche et al., 2016),
thus compromising the completion of autophagy.
2.4. Ageing and impaired proteostasis in Huntington’s disease
The age of onset in HD correlates inversely with the number of CAG
repeats in the Htt gene (Finkbeiner, 2011). Still, notwithstanding rare
infantile/juvenile forms of the disease, most patients express HD alleles
with ∼40-50 CAG from early-life and typically become symptomatic
only around mid-life (Hands et al., 2008). This delayed onset implicates
biological ageing in disease manifestation, and although the detailed
mechanisms remain unclear, two non-mutually exclusive hypotheses
are increasingly supported by experimental evidence.
One hypothesis is that mHtt accelerates the eﬀects of ageing on
cellular function (Gasset-Rosa et al., 2017; Horvath et al., 2016). This is
supported by the increased accumulation of epigenetic ageing markers
in the brain of HD patients versus controls (Horvath et al., 2016), and by
the delay of disease progression in HD mouse models submitted to
strategies that extend lifespan (Sadagurski et al., 2011; Tallaksen-
Greene et al., 2014). From a mechanistic perspective, the expression of
mHtt in neurons exacerbates age-dependent defects on nuclear integrity
and nucleocytoplasmic transport (Gasset-Rosa et al., 2017). Ad-
ditionally, mHtt induces a proteotoxic stress that disrupts ER and cy-
tosolic redox homeostasis, a pattern observed in ageing C. elegans and
also in C. elegans expressing expanded polyQ protein (Kirstein et al.,
2015).
Another hypothesis is that ageing challenges cellular homeostasis
and renders cells more vulnerable to mHtt toxicity (Kaushik and
Cuervo, 2015; Saxena and Caroni, 2011). HD animal models present
age-dependent increases in mHtt aggregate load and in motor/neuro-
degenerative phenotypes (Diguet et al., 2009; Marcellin et al., 2012;
Morley et al., 2002). Mechanistically, the decline in mitochondrial
function and in proteostasis capacity may be two of the main factors
contributing to increased vulnerability to mHtt toxicity with age
(Labbadia and Morimoto, 2015; Sun et al., 2016). Recently, a single-cell
transcriptome atlas of the Drosophila brain showed that the expression
of OXPHOS genes declines faster during ageing in comparison to other
genes, and that this decline was accompanied by decreased mitochon-
drial turnover (Davie et al., 2018). The accumulation of dysfunctional
mitochondria decreases ATP availability and disrupts redox home-
ostasis (Sun et al., 2016), with a widespread cellular eﬀect. Speciﬁcally,
the resulting ATP depletion and increased reactive oxygen species
(ROS) generation may impair the UPS (Segref et al., 2014) and mole-
cular chaperones (Grunwald et al., 2014), thus compromising cellular
proteostasis and increasing mHtt aggregate load (Pinho et al., in press).
The decline of proteostasis capacity with ageing is evidenced by
alterations in the composition and activity of key components of the
proteostasis network. Ageing human brains present decreased levels of
ATP-dependent chaperones, such as Hsp70, Hsp90 or the CCT/TRiC
complex (Brehme et al., 2014). Additionally, ageing C. elegans show
reduced levels of mitochondrial chaperones and impaired activation of
stress responses such as the heat shock response or the ER and mi-
tochondrial stress responses (Dues et al., 2016; Liang et al., 2014). In-
terestingly, decreases in chaperones or impaired activation of stress
responses in HD models correlate with increased polyQ aggregation and
toxicity (Brehme et al., 2014; Labbadia et al., 2011). The importance of
age-dependent proteome changes to mHtt toxicity may also be inferred
from induced pluripotent stem cell (iPSCs) models. Downregulation of
the ubiquitin ligase UBR5 during iPSC diﬀerentiation, or UBR5 knock-
down, impaired the proteasomal degradation of mHtt, increasing mHtt
aggregation and toxicity, and suggesting that a decline of UBR5 during
ageing may aggravate HD pathology (Koyuncu et al., 2018).
Overall, the proteome changes that accompany ageing contribute
for the proteostasis collapse in adult-onset HD, and support therapeutic
strategies that aim to enhance proteostasis capacity (Fig. 1). It remains
unclear, however, if the alterations of the proteome with age occur
gradually or more abruptly. While the conventional ageing model
proposes a gradual decline in proteostasis capacity until reaching a
disease threshold, there are also alternative models supported by data
in the invertebrate C. elegans that suggest a general or tissue-speciﬁc
collapse of programmed proteostasis in early adulthood (Labbadia and
Morimoto, 2015). While further research is needed, such alternative
models may provide new insights into the mechanisms of selective
vulnerability and adult-onset neurodegeneration.
3. Section II - Strategies to alleviate impaired proteostasis in HD
3.1. Modulating molecular chaperones
Molecular chaperones are therapeutic targets in neurodegenerative
disorders, where failure in their activity contributes to the accumula-
tion of misfolded proteins (Papsdorf and Richter, 2014; Reis et al.,
2017). The levels of diﬀerent chaperones were progressively reduced in
brains of HD mice (Neueder et al., 2017; Yamanaka et al., 2008).
Moreover, mHtt limits chaperone availability by competing with other
client proteins for chaperone binding (Hipp et al., 2012), and by se-
questering chaperones in mHtt aggregates (Park et al., 2013; Yu et al.,
2014). Potential strategies to increase chaperone activity in HD include
the activation of the heat shock response and the direct modulation of
speciﬁc chaperones (Kalmar and Greensmith, 2017).
The levels of heat shock factor 1 (Hsf1 – a key activator of the heat
shock response; Anckar and Sistonen, 2011) are decreased in mouse and
human HD brains (Gomez-Pastor et al., 2017). The proposed
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mechanism is that mHtt induces the CK2a kinase and the Fbxw7 E3
ligase, which respectively phosphorylate and ubiquitinate Hsf1, thereby
promoting its proteasomal degradation (Gomez-Pastor et al., 2017).
Preventing Hsf1 degradation with the CK2 kinase inhibitors TID43 or
emodin, or by increasing Hsf1 activity with azadiradione, reduced mHtt
aggregation and attenuated disease progression in HD mice (Gomez-
Pastor et al., 2017; Singh et al., 2018).
The direct modulation of speciﬁc chaperones of the Hsp70 and
Hsp90 chaperone families is another potential therapeutic strategy in
HD (Pratt et al., 2015; Reis et al., 2017). Hsp70 and Hsp90 are involved
in mHtt triage, but while Hsp70 interacts with proteins at an early stage
of folding, either assisting their folding or redirecting them for de-
gradation, Hsp90 acts in late folding stages, stabilizing and inhibiting
client protein ubiquitination (Karagoz and Rudiger, 2015; Pratt et al.,
2015). Hsp90 is thought to mediate mHtt accumulation and aggrega-
tion through the recruitment of the deubiquitinase Usp19 – which
deubiquitinates mHtt and thus decreases its elimination (He et al.,
2017, 2016). Pharmacological inhibition of Hsp90 with NVP-AUY992
increased mHtt degradation through the UPS by inhibiting the forma-
tion of the Hsp90-mHtt complex, leaving mHtt free to become a sub-
strate for UPS degradation (Baldo et al., 2012). Hsp90 inhibition can
also elicit the heat shock response through the dissociation of the
complex Hsf1-Hsp90. Hsf1 dissociation from the complex enables Hsf1
activation and consequent upregulation of several chaperones, which
will attempt to correct mHtt conformation or target it for degradation
(Jackrel and Shorter, 2011). Accordingly, treatment with HSP990, an
Hsp90 inhibitor, increased the levels of Hsp70 and Hsp40, and tran-
siently ameliorated motor performance and decreased mHtt aggregate
load in R6/2 mice (Labbadia et al., 2011).
Overexpression of Hsp70 decreased mHtt aggregation in cellular
and animal models of HD (Guzhova et al., 2011; Hay et al., 2004),
whereas Hsp70 deletion increased the size of mHtt aggregates and ex-
acerbated the mHtt induced phenotype in R6/2 mice (Wacker et al.,
2009). Hsp70 acts in combination with other chaperones to mediate
protein disaggregation (Nillegoda et al., 2018). Hsp70 forms a trimeric
complex with Hsp40 and Hsp110 that regulates mHtt solubility through
disaggregation of mHtt ﬁbrils (Scior et al., 2018). Recent data indicate
that Hsp40 is the limiting chaperone for the disaggregation activity,
since increasing Hsp40 suﬃced to increase the eﬃciency of the com-
plex to suppress mHtt ﬁbrilization (Scior et al., 2018).
Proteins that fail to reach proper folding states after cycling with
Hsp70 can be transferred to another group of molecular chaperones
called chaperonins. Chaperonins are cylindrical complexes that en-
capsulate and fold single protein chains (Kim et al., 2013). Experiments
manipulating expression levels of one of these chaperonins −CCT
(chaperonin containing TCP-1; TRiC) – suggest that CCT reduces mHtt
levels and prevents its aggregation (Tam et al., 2006; Zhao et al.,
2016b). The eﬀect of CCT in mHtt proteostasis was primarily attributed
to its function as a chaperonin (Tam et al., 2006), however, more re-
cently, it has been proposed that CCT may regulate mHtt levels through
indirect mechanisms involving the protein degradation pathways. In
the BACHD mouse model, CCT overexpression reduced mHtt by en-
hancing its proteasomal degradation (Zhao et al., 2016b). In HeLa cells
expressing mHtt constructs, CCT knockdown impaired the autophagic
ﬂux and increased mHtt aggregation, due to a loss of function of CCT in
actin folding, disrupting the cytoskeleton, and consequently in-
tracellular transport or autophagosomal biogenesis and degradation
(Kast and Dominguez, 2017; Pavel et al., 2016). The function of CCT in
actin folding may also explain why CCT overexpression was able to
rescue BDNF and lysosomal transport in in vivo HD models (Zhao et al.,
2016b).
Collectively, in addition to modulation of Hsp70 and Hsp90, these
data support the modulation of other chaperone families, such as Hsp40
and chaperonins, alone or in combination with Hsp70/90, as potential
therapeutic strategies in HD.
3.2. Modulating the ubiquitin-proteasome system
The UPS is one of the main routes for degradation of misfolded
proteins, and its impairment has been associated with several neuro-
degenerative diseases, including HD (McKinnon and Tabrizi, 2014).
Impairment of the UPS in HD has been attributed to an ineﬃcient
targeting of soluble mHtt for proteasomal degradation (Bhat et al.,
2014) and, more recently, to the inhibition of 26S proteasome gate
opening by soluble oligomeric mHtt species (Thibaudeau et al., 2018).
This provides a rationale to enhance UPS activity as a therapeutic
strategy, and this has been tested in HD models through the modulation
of proteasome subunits and of ubiquitin-interacting proteins, such as
ubiquitin ligases, ubiquilins, and deubiquitinases (Eletr and Wilkinson,
2014; McKinnon and Tabrizi, 2014; Ristic et al., 2014).
Direct proteasome modulation via overexpression of the proteasome
activator PA28ɣ increased cell viability in HD neuronal models (Seo
et al., 2007). Subsequent in vivo studies showed that PA28ɣ over-
expression rescued HD phenotypes in YAC128 mice (Jeon et al., 2016),
whereas overexpression of the proteasomal pbs-5 catalytic subunit in-
creased resistance to proteotoxic stress and ameliorated motor pheno-
types in HD nematodes (Chondrogianni et al., 2015).
The overexpression of E3 ubiquitin ligases such as CHIP, Ube3, Herp
or UBR5, is a potential strategy to decrease mHtt aggregation, by pro-
moting its ubiquitination and proteasomal degradation (Bhat et al.,
2014; Jana et al., 2005; Luo et al., 2018) (Koyuncu et al., 2018). The
related strategy of overexpressing proteins that recruit ubiquitin ligases,
such as NUB1 (negative regulator of ubiquitin-like protein 1), reduced
mHtt neurotoxicity in ﬂies (Aron et al., 2013; Lu et al., 2013). Alter-
natively, one might target proteasomal shuttles, such as ubiquilin-2,
which cooperates with the Hsp70-Hsp110 disaggregase machinery, and
mediates the delivery of Hsp70-bound mHtt to the proteasome for de-
gradation (Hjerpe et al., 2016) (Fig. 2).
Inhibition of the proteasome-associated deubiquitinase Usp14, with
the small molecule inhibitor IU1, decreased levels of disease-associated
proteins in cell models of the polyQ disorder SCA3, Alzheimer′s disease,
amyotrophic lateral sclerosis, and Prion disease (Lee et al., 2010;
McKinnon et al., 2016). The authors proposed that a premature deu-
biquitination of the substrates by Usp14 allows them to escape pro-
teasomal degradation, and thus inhibiting Usp14 with IU1 increases
substrate degradation (Lee et al., 2010, 2016). We found no published
studies testing this Usp14 inhibition strategy in HD models. In contrast,
Usp14 overexpression reduced aggregates and death in cells expressing
mHtt (Hyrskyluoto et al., 2014).
Unlike the premature deubiquitination hypothesis, the Usp14
overexpression strategy aims to deubiquitinate mHtt aggregates making
them more accessible to proteasomal degradation (Hyrskyluoto et al.,
2014). Additionally, Usp14 overexpression inhibited IRE1α phosphor-
ylation, thus preventing mHtt from inducing an ER stress pathway that
impairs autophagy and increases mHtt accumulation (Hyrskyluoto
et al., 2014; Lee et al., 2012). While further studies are necessary to
clarify the role of the deubiquitinase Usp14 in mHtt proteostasis, cur-
rent data suggest it plays a dual role, regulating accessibility of ubi-
quitinated mHtt to the UPS, and also limiting mHtt-induced ER stress
(Fig. 2).
Enhancement of the UPS activity has the potential to decrease mHtt
soluble levels, mHtt aggregation and its induced cytotoxicity. While
genetic strategies have thus far been the predominant approach to
modulate the UPS, pharmacological investigations are likely to increase
with the recent development of chemical modulators of the UPS
pathway (Collins et al., 2017; Khan and Nelson, 2018; Leestemaker
et al., 2017).
3.3. Modulating autophagy
Autophagy is regulated through pathways that sense the cellular
energy status, nutrient supply, and the availability of growth factors.
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The initial step of autophagosome formation is primarily mediated by
the ULK1 complex, whose activity is regulated by two major upstream
kinases: mTORC1 (mammalian target of rapamycin – mTOR, complex
1) and AMPK (AMP activated kinase) (Hurley and Young, 2017). Under
conditions of nutrient availability, mTORC1 inhibits ULK1 by phos-
phorylation at Ser 757, suppressing autophagosome formation. Under
conditions of nutrient deprivation (starvation), AMPK activates ULK1
directly via phosphorylation at Ser 317 and Ser 777, and indirectly
through inhibition of mTORC1 (Kim et al., 2011) (Fig. 3). The mod-
ulation of mTORC1 and AMPK activities can thus regulate autophagy
and, to date, these have been two of the most extensively studied
strategies to modulate autophagy in HD models (Crino, 2016;
Vingtdeux et al., 2011).
Despite earlier indications that the inhibition of mTORC1 has ben-
eﬁcial eﬀects in HD models (Ravikumar et al., 2004; Roscic et al.,
2011), more recently, the restoration of mTORC1 activity was shown to
improve motor deﬁcits and brain pathology in HD mice (Lee et al.,
2015). mTORC1 activity was reduced in the striatum of HD patients and
also in the striatum of N171-81Q mice (Lee et al., 2015). Moreover, in
N171-81Q mice, the expression of the constitutively active form of the
mTORC1 activator Rheb (Ras homolog enriched in brain) upregulated
basal autophagy and increased mHtt clearance (Lee et al., 2015). Ad-
ditionally, disease phenotypes were also rescued in N171-81Q mice by
exogenous expression of Rhes (Ras homolog enriched in striatum; (Lee
et al., 2015). Nevertheless, the precise role of mTORC1 activity and
Rhes in HD pathology remains controversial.
Rhes was shown to interact with mHtt and promote its cytotoxicity
(Subramaniam et al., 2009). Rhes deletion improved disease progres-
sion in HD mice (Baiamonte et al., 2013; Mealer et al., 2013; Swarnkar
et al., 2015), whereas ectopic Rhes expression in the cerebellum of HD
mice exacerbated the disease phenotype (Swarnkar et al., 2015). There
is evidence that Rhes promotes autophagy in cells, but in an mTORC1-
independent manner by binding to beclin-1 and reducing its inhibitory
interaction with Bcl-2 (Mealer et al., 2014). The interaction with mHtt
seems to block such autophagy-promoting activity of Rhes, thus con-
tributing to impairment of autophagy (Mealer et al., 2014) (Fig. 3).
The modulation of mTOR-independent autophagy has shown pro-
mising results in HD models. Pharmacological activation or expression
of constitutively active AMPK induced autophagy in an mTOR-in-
dependent manner, reduced mHtt aggregates and improved cell viabi-
lity (Walter et al., 2016). Pharmacological induction of autophagy with
the Akt inhibitor 10-NCP reduced mHtt levels and improved survival of
Fig. 2. Modulation of the UPS in HD. (A) The E3 ubiquitin ligase CHIP polyubiquitinates mHtt bound to Hsp70, targeting mHtt for proteasomal degradation (Jana
et al., 2005; Kettern et al., 2010; Reeg et al., 2016). The deubiquitinase Usp14 removes the ubiquitin (ub) chains and increases the accessibility of mHtt for
proteasomal degradation (Hyrskyluoto et al., 2014). Premature deubiquitination by Usp14 may allow substrates to escape degradation (Lee et al., 2010, 2016), see
section “Modulating the ubiquitin-proteasome system” for details. (B) Left: mHtt decreases the interaction between Usp14 and the ER stress transducer IRE1α, enhancing
phosphorylation and activation of IRE1α. Right: increased expression of Usp14 limits IRE1α activation, reducing mHtt-induced ER stress (Hyrskyluoto et al., 2014).
(C) Ubiquilin 2 (ubqln2) recognizes mHtt aggregates bound to the disaggregase complex Hsp70-Hsp40-Hsp110. Following disaggregation, ubiquilin 2 shuttles mHtt
to the proteasome, promoting its degradation (Hjerpe et al., 2016).
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striatal neurons (Tsvetkov et al., 2010), while inhibition of the alpha-
tubulin deacetylase HDAC6 with tubastatin A promoted autophagic ﬂux
and decreased mHtt levels in striatal neurons (Guedes-Dias et al.,
2015). Despite the encouraging results of indirectly modulating au-
tophagy by targeting mTOR-dependent and mTOR-independent path-
ways, there has recently been an increased eﬀort to identify strategies
to modulate autophagy more directly. One such strategy is regulating
the activity of the autophagy initiation complex ULK1.
The activity of ULK1 seems to be decreased in the brains of zQ175
HD mice, as suggested by the decreased phosphorylation of ULK1
substrates Beclin-1 and Atg14, together with the redistribution of ULK1
to an insoluble fraction where aggregated mHtt was found (Wold et al.,
2016). In turn, overexpression of wild-type ULK1 but not that of a ki-
nase inactive form of ULK1, decreased insoluble mHtt levels in cell
lines, suggesting that ULK1 kinase activity is a limiting factor for the
autophagic clearance of mHtt (Wold et al., 2016). The direct modula-
tion of ULK1 activity thus shows potential to modify mHtt load, an
exciting hypothesis that is now possible to test with the recent devel-
opment of ULK1 activators (Zhang et al., 2017) and ULK1 inhibitors
(Egan et al., 2015; Lazarus et al., 2015; Lazarus and Shokat, 2015;
Petherick et al., 2015).
Lastly, there is increased evidence that mHtt clearance may be also
regulated by chaperone-mediated autophagy (CMA; Bauer et al., 2010;
Koga et al., 2011; Qi et al., 2012; Thompson et al., 2009). These ﬁnd-
ings have promoted the search for small molecule inducers of CMA.
Given that signalling via the retinoic acid receptor α (RARα) seems to
inhibit CMA, RARα antagonists are being investigated as chemical en-
hancers of CMA to tackle proteotoxicity in neurodegenerative disorders
and ageing (Anguiano et al., 2013). Still, as several components in-
volved in autophagy and CMA decline with age (Kaushik and Cuervo,
2015), complementary strategies to modulate the Htt proteostasis net-
work in HD are being actively pursued, namely the modulation of Htt
post translational modiﬁcations.
3.4. Modulating huntingtin post translational modiﬁcations
Post translational modiﬁcations (PTMs) are key modulators of Htt
conformation, regulating its interaction with other proteins, its stabi-
lity, aggregation, subcellular localization and clearance (Ehrnhoefer
et al., 2011). The presence of expanded polyQ signiﬁcantly alters PTMs.
Among them, proteolytic cleavage, phosphorylation, acetylation, ubi-
quitination, and SUMOylation have all been shown to alter Htt pro-
teostasis, and modulation of each of these represents a potential ther-
apeutic strategy.
Proteolytic cleavage of mHtt yields toxic N-terminal fragments
containing expanded polyQ (Ehrnhoefer et al., 2011). The activity of
the protease caspase 6 is increased in HD (Graham et al., 2010), pos-
sibly because mHtt hinders the normal inhibitory binding of wild-type
Htt to the proform of caspase 6 (Riechers et al., 2016). Caspase 6
cleaves Htt at the amino acid 586. Expression of the resulting mHtt-586
N-terminal fragment aggravates the phenotype of HD mice (Waldron-
Roby et al., 2012), whereas a 586 cleavage-resistant mutant or caspase
6 knockout attenuates the phenotype (Gafni et al., 2012; Graham et al.,
2006; Pouladi et al., 2009; Wong et al., 2015). While these studies
highlight the toxicity of N-terminal fragments, C-terminal fragments
have also been proposed to play a role in HD pathophysiology. The
presence of an Htt C-terminal fragment in in vitro and in vivo HD models
induced ER toxicity, possibly through a mechanism that inhibits dy-
namin-1, a GTPase involved in endocytic membrane fusion and recently
found in the ER (El-Daher et al., 2015). Still, further studies are ne-
cessary to clarify the diﬀerential proteostasis and toxicity of the Htt C-
terminal fragment in wild-type versus mHtt-expressing cells.
The Htt N-terminal has multiple phosphorylation sites that regulate
Htt conformation, its interaction with other proteins, and also its pro-
teolytic accessibility (Guo et al., 2018). Mutant Htt is less phosphory-
lated than the wild-type form, and increased phosphorylation at speciﬁc
residues decreases mHtt toxicity (Thompson et al., 2009). The ﬁrst 17
acids contain a cytoplasmic retention signal (CRS) and three phos-
phorylation residues (T3, S13, and S16) (Ehrnhoefer et al., 2011). S13
and S16 phosphorylation alter the CRS, increasing mHtt nuclear loca-
lization (Atwal et al., 2011; Thompson et al., 2009) and reducing
neuronal death (Arbez et al., 2017). S421 phosphorylation increased
mHtt proteasomal degradation and rescued neurodegeneration in HD
mice (Kratter et al., 2016). Interestingly, the phospho-null S1201 A
mutation reduced mHtt neurotoxicity (Arbez et al., 2017), while also
increasing its nuclear localization (Ratovitski et al., 2017), which may
tag mHtt for proteasomal and lysosomal degradation (Greiner and
Yang, 2011; Thompson et al., 2009). Concerning mHtt conformation
Fig. 3. Modulation of autophagy in HD. In
starvation induced autophagy (nutrient and en-
ergy depletion), AMPK activates ULK1 (via its
phosphorylation at serines 317 and 777) and
inhibits mTOR, preventing its inhibitory phos-
phorylation of ULK1 at serine 757 (Kim et al.,
2011). In mTOR-independent autophagy, AMPK
phosphorylates ULK1 without aﬀecting mTOR
activity (Walter et al., 2016). Rhes may also
induce mTOR-independent autophagy by re-
leasing Beclin-1 from the inhibitory eﬀect of
Bcl2 (Mealer et al., 2014). mHtt may block this
eﬀect of Rhes, contributing to autophagy im-
pairment in HD (Mealer et al., 2014). In selec-
tive autophagy, wild-type Htt may act as a
scaﬀold that bridges autophagy recognition
and activating machinery (p62 and ULK1, re-
spectively), and releases ULK1 from the in-
hibitory eﬀect of mTOR (Rui et al., 2015a).
Active ULK1 phosphorylates Beclin-1, leading
to autophagy activation.
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and aggregation, S13 and S16 phosphorylation reduced the mHtt con-
formational rigidity caused by the polyQ expansion (Daldin et al.,
2017) and decreased its aggregation in human cells (Branco-Santos
et al., 2017). Similarly, increasing mHtt T3 phosphorylation, which is
strongly decreased in HD mice and human cells, reduced its con-
formational rigidity (Cariulo et al., 2017; Chiki et al., 2017) and re-
duced aggregation in HD ﬂies (Branco-Santos et al., 2017).
In contrast to phosphorylation, mHtt is preferentially acetylated
compared to the wild-type form (Ehrnhoefer et al., 2011). Acetylation
at lysine K6 reversed the inhibitory eﬀect that T3 phosphorylation had
on mHtt aggregation in vitro (Chiki et al., 2017). K444 acetylation was
found in mutant, but not wild-type, Htt, and was proposed to facilitate
traﬃcking of mHtt into autophagosomes, increasing its autophagic
clearance and reducing its toxic eﬀects in primary neurons and in a C.
elegans HD model (Jeong et al., 2009).
Htt ubiquitination, particularly at lysines K6, K9 and K15, increases
its degradation (Martin et al., 2015). In contrast, SUMOylation – the
attachment of small-ubiquitin-like modiﬁers (SUMO), competes with
ubiquitination, promoting mHtt stability and reduced aggregation,
which increases its potential to exert toxic eﬀects (Steﬀan et al., 2004).
The knockout of E3-SUMO ligases improved disease phenotypes in HD
mice. In particular, PIAS1 knockdown in HD mice decreased mHtt in-
clusions, the accumulation of ubiquitinated and SUMOylated proteins,
and also ameliorated the inﬂammatory and behavioural phenotypes
(Ochaba et al., 2016).
3.5. Modulating mitochondria
Given the several pathways by which mitochondrial dysfunction
may impair cellular proteostasis, one potential strategy to restore pro-
teostasis in neurodegenerative disorders might be to rescue mitochon-
drial function. The modulation of mitochondrial metabolism and
bioenergetics is under active research in this context (Sorrentino et al.,
2018). Treatment with MSDC-0160, an inhibitor of the mitochondrial
pyruvate carrier, ameliorated the pathology in cell and mammalian
models of Parkinson′s disease, through a mechanism involving inhibi-
tion of mTOR and induction of autophagy (Ghosh et al., 2016). In
cellular and mouse models of HD, treatment with butyrate or phe-
nylbutyrate enhanced pyruvate dehydrogenase activity and this was
associated with a rescue of mitochondrial metabolic function and motor
phenotypes (Naia et al., 2017a). Also, treatment with resveratrol was
linked with sirtuin 1 activation and a rescue of mitochondrial function
in cellular HD models and motor phenotypes in YAC128 HD mice (Naia
et al., 2017b). Still, given the pleiotropic eﬀects of resveratrol on mi-
tochondria, further studies are warranted to understand its metabolic
targets (Sorrentino et al., 2018).
The rescue of mitochondrial function by decreasing oxidative stress
or by modulating mitochondrial dynamics has also been tested in HD
models (Damiano et al., 2010). Treatment of the STHdhQ111/Q111 cell
line with the mitochondria-targeted antioxidant MitoQ was found to
alter the expression of genes involved in mitochondrial ﬁssion-fusion
dynamics (Yin et al., 2016). In mouse models of other neurodegen-
erative disorders, such as Alzheimer’s disease and spinocerebellar
ataxia type I, treatment with of MitoQ was found to rescue mitochon-
drial impairments and disease phenotypes (McManus et al., 2011). In
HD cell line models, treatment with the compound mdivi-1 promoted
mitochondrial fusion, an eﬀect that was associated with the inhibition
of excessive mitochondrial ﬁssion (Manczak and Reddy, 2015), al-
though this mechanism of mdivi-1 activity has been recently questioned
and instead attributed to the modulation of mitochondrial ROS pro-
duction (Bordt et al., 2017).
The enhancement of mitochondrial proteostasis mechanisms is
currently being explored as a means to alleviate the cytosolic proteos-
tasis machinery and reduce the proteotoxicity of misfolded proteins
(Ruan et al., 2017). The genetic and pharmacological enhancement of
mitochondrial proteostasis, in a C. elegans model of amyloid-β (Aβ)
proteotoxicity, decreased Aβ aggregation and Aβ-induced toxicity
(Sorrentino et al., 2017). In C. elegans expressing mHtt, the induction of
mitochondrial proteostasis, by mild perturbation of the electron trans-
port chain, reduced mHtt-induced toxicity and polyQ aggregation with
age (Kim et al., 2016; Labbadia et al., 2017). Similar results were ob-
served when mitochondrial proteostasis was induced by reduction of
mitochondrial Hsp70 levels or by inhibition of fatty acid import (Kim
et al., 2016). Interestingly, in this case, the induction of mitochondrial
proteostasis was also accompanied by an induction of the cytosolic heat
shock response, suggesting that mitochondria can signal cytosolic pro-
teostasis as an attempt to maintain cellular homeostasis (Kim et al.,
2016). Overall, these ﬁndings support the modulation of mitochondrial
proteostasis as an avenue to recover impaired proteostasis in HD,
linking mitochondrial (dys)function with cytosolic stress responses.
4. Concluding remarks
The current model to account for the impairment of proteostasis by
mHtt proposes a gradual, yet global collapse of the proteostasis network
that synergises with ageing-associated changes in proteostasis capacity.
Molecular chaperones, proteolytic pathways such as the UPS and au-
tophagy, and Htt PTMs are among the most intensively tested ther-
apeutic targets. Studies on the role of the RQC system for mHtt pro-
teostasis, and also of the impact of the unfolded protein responses of the
ER and mitochondria upon cellular proteostasis, are opening new pos-
sibilities for experimental therapeutics.
A long standing question in HD research is how the ubiquitously
expressed mHtt preferentially kills neurons, particularly medium spiny
striatal neurons (Margulis and Finkbeiner, 2014). Intrinsic diﬀerences
in the proteostasis system among cellular populations may contribute to
this diﬀerential vulnerability. Consistently, the clearance of soluble
mHtt seems slower in neurons than in astrocytes, and also slower in
striatal than in cortical neurons (Zhao et al., 2016a). This diﬀerential
mHtt proteostasis was attributed to a preferential clearance of mHtt by
the UPS (Zhao et al., 2016a). Accordingly, UPS activity seems higher in
astrocytes than neurons (Tydlacka et al., 2008), and cortical neurons
expressing mHtt present a higher dependence on the UPS than striatal
neurons (Tsvetkov et al., 2013). These ﬁndings support the enhance-
ment of UPS activity to reduce neuronal vulnerability in HD.
A more recent question in the HD ﬁeld is whether Htt acts as a
scaﬀold in the autophagy process. This hypothesis is now further sup-
ported by evidence that Htt interacts with autophagy inducers such as
ULK1 (Rui et al., 2015a), whose activity was recently found reduced in
HD models (Wold et al., 2016), possibly contributing to autophagy
impairment in HD. Importantly, ULK1 modulators are emerging in the
context of cancer research (Egan et al., 2015; Zhang et al., 2017) and it
will be interesting to evaluate their potential in the context of protein-
misfolding diseases.
In addition to directly targeting the UPS and autophagy pathways,
the clearance of mHtt may also be regulated by modulating molecular
chaperones. Thus far, the most common approaches in the context of
HD have been Hsp70 and Hsp90 modulation (Reis et al., 2017). How-
ever, the modulation of other chaperones, such as Hsp40, which co-
operates with Hsp70 to mediate mHtt disaggregation (Scior et al.,
2018), and chaperonins like CCT, which may intervene when Hsp70
folding activity fails and prevent mHtt aggregation (Kim et al., 2013;
Tam et al., 2006), arise as potential therapeutic strategies in HD.
Other attempts to enhance cytosolic proteostasis may involve the
modulation of the unfolded protein response of organelles such as the
ER or mitochondria (Rahman et al., 2018; Sorrentino et al., 2017).
Regarding the ER, many neurodegenerative diseases, including HD,
have been associated with chronic activation of the ER stress response
(Hyrskyluoto et al., 2014; Remondelli and Renna, 2017; Zhou et al.,
2018). Increasing the ER folding capacity may thus be beneﬁcial for HD
treatment. Accordingly, modulation of protein disulphide isomerase, an
ER chaperone, increased the life span and ameliorated motor
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dysfunction and brain atrophy in HD mice (Zhou et al., 2018). Re-
garding mitochondria, this organelle was recently proposed as a site for
degradation of cytosolic aggregates (Ruan et al., 2017). Moreover, en-
hancing mitochondrial proteostasis reduced mHtt aggregation and
toxicity (Labbadia et al., 2017). Mitochondria contain their own set of
chaperones and proteostasis machinery with the potential of being
modulated (Braun and Westermann, 2017). Inhibitors of mitochondrial
proteases are being developed, however, they still require improve-
ments in speciﬁcity and further characterization of their mechanism of
action (Goard and Schimmer, 2014).
HD thus far remains an incurable disease without eﬀective treat-
ment. Nevertheless, there is a growing understanding of the interaction
between the diﬀerent elements of the proteostasis network and dif-
ferent mHtt species. This may soon provide an integrated view of how
diﬀerential proteostasis inﬂuences neuronal vulnerability. New mole-
cules targeting diﬀerent elements of the proteostasis network are cur-
rently emerging, bringing exciting prospects for the future pharmaco-
logical management of HD and related disorders.
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